Shots:
- Oxford BioTherapeutics has entered into a multi-year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next-generation T-cell engager therapies targeting solid tumors
- Under the agreement, OBT will leverage its OGAP-Verify platform to identify tumor-selective targets and design & delivery of developed candidates, while Bristol Myers Squibb will lead subsequent clinical research, development and commercialization
- OBT will receive an upfront payment including research funding and is eligible for milestone payments and royalties on net sales; the deal marks OBT’s third major pharma collaboration in the past 12 months
Ref: Oxford BioTherapeutics | Image: Oxford BioTherapeutics | Press Release
Related News:BMS Reports P-III (SCOUT-HCM) Trial Data on Camzyos in Symptomatic Obstructive Hypertrophic Cardiom…
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
